Retension Pharmaceuticals adopts amended and restated bylaws ahead of IPO close

Retension Pharmaceuticals adopted amended and restated bylaws that took effect immediately before its IPO closing on Oct. 13, 2026. The updated bylaws had been authorized by the board and stockholders ahead of the offering. A third amended and restated certificate of incorporation was filed in Delaware on Oct. 9, 2026, also tied to the IPO. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Retension Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-109024), on October 13, 2026, and is solely responsible for the information contained therein. (C)